Dr. Thomas Lee Maglinao Jr., MD

Dr. Maglinao practices at Kuakini Medical Center in Honolulu, Hawaii, part of Kuakini Health System.

Dr. Maglinao's NPI, 1609108315, was assigned on February 4, 2010. Dr. Maglinao holds Hawaii license MDR5837.

Dr. Maglinao's primary practice is Kuakini Medical Center, at 347 North Kuakini Street, Honolulu, HI 96817 in Honolulu County. The practice phone is (808) 536-2236.

Dr. Maglinao's primary practice is Kuakini Medical Center in Honolulu, Hawaii, part of Kuakini Health System. Dmand AI also links Dr. Maglinao to 1 physician office, 1 hospice and 1 skilled nursing facility, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maglinao practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Maglinao's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Maglinao is licensed in Hawaii.

CMS data shows 1,014 Medicare services from Dr. Maglinao across 7 procedure codes in 2024, for 202 Medicare patients. Medicare paid $90,106 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 202 Medicare patients who saw Dr. Maglinao in 2024. The largest group is 85 and over, with 85 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maglinao's median patient age at 81, with 53% women.

In 2024, Dr. Maglinao wrote 940 Medicare Part D claims for 278 patients. 88% of them were for generic drugs. CMS names the drug for 543 of them, across 29 drugs with 11 or more claims each, at $31,480 in total drug cost. In 2023, CMS named 505 claims across 27 drugs.

Dr. Maglinao accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 227 general payments to Dr. Maglinao from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $2,237.